The coenzyme Q10 analog idebenone attenuates murine lupus by improving mitochondrial metabolism and reducing inflammation.
A role for mitochondrial dysfunction has been proposed in the immune dysregulation and organ damage characteristic of systemic lupus erythematosus (SLE). Idebenone is a coenzyme Q10 synthetic quinone analog and an antioxidant that has been used in humans to treat diverse diseases where mitochondrial function is impaired. This study assessed if idebenone ameliorates murine lupus. Idebenone was administered orally to MRL/lpr mice at two different doses (either 1 or 1.5 g/kg diet) for 8 weeks. At peak disease activity, clinical, immunologic and metabolic parameters were analyzed and compared to untreated mice. Results were confirmed in the lupus-prone NZM2328 mouse model. In MRL/lpr mice, idebenone-treated mice showed significant attenuation in mortality (p<0.01) and in several features including glomerular inflammation and fibrosis (p<0.05) and renal function, in association with decreases in renal IL-17A and mature IL-18 expression. Levels of splenic proinflammatory cytokines and inflammasome-related genes were significantly decreased by idebenone, while no obvious toxicity was observed. Idebenone inhibited neutrophil extracellular trap formation in lupus mouse and human neutrophils. Idebenone also improved mitochondrial metabolism (30% increase in basal respiration and ATP production), reduced heart lipid peroxidation in half , and significantly improved endothelium-dependent vasorelaxation. NZM2328 mice exposed to idebenone also displayed improvements in renal and systemic inflammation. Idebenone ameliorates murine lupus disease activity and organ damage severity supporting the hypothesis that agents that modulate mitochondrial biology may have a therapeutic role in SLE.